Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Preferred Stock Liabilities: 2019

Historic Preferred Stock Liabilities for C4 Therapeutics (CCCC) over the last 1 years, with Dec 2019 value amounting to $111.0 million.

  • C4 Therapeutics' Preferred Stock Liabilities rose 133.21% to $256.5 million in Q3 2020 from the same period last year, while for Sep 2020 it was $256.5 million, marking a year-over-year increase of 133.21%. This contributed to the annual value of $111.0 million for FY2019, which is N/A change from last year.
  • Per C4 Therapeutics' latest filing, its Preferred Stock Liabilities stood at $111.0 million for FY2019.
  • C4 Therapeutics' Preferred Stock Liabilities' 5-year high stood at $111.0 million during FY2019, with a 5-year trough of $111.0 million in FY2019.
  • Its 1-year average for Preferred Stock Liabilities is $111.0 million, with a median of $111.0 million in 2019.